Literature DB >> 11760782

Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia.

K Höfner1, M Oelke, S Machtens, V Grünewald.   

Abstract

Trospium chloride (TCL), a quaternary ammonium derivative of nortropanol, has been evaluated in a number of clinical and pharmacological studies. Selected pharmacological and clinical pharmacokinetic data are discussed as providing a basis for a better interpretation and understanding of the clinical trial results. An overview of the results of 20 clinical trials and post-marketing surveillance studies including more than 10000 patients is presented.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11760782     DOI: 10.1007/s003450100225

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  12 in total

Review 1.  Trospium chloride: a quaternary amine with unique pharmacologic properties.

Authors:  Raymond W Pak; Steven P Petrou; David R Staskin
Journal:  Curr Urol Rep       Date:  2003-12       Impact factor: 3.092

Review 2.  Update on overactive bladder: pharmacologic approaches on the horizon.

Authors:  Eric S Rovner; Alan J Wein
Journal:  Curr Urol Rep       Date:  2003-10       Impact factor: 3.092

Review 3.  Clinical pharmacokinetics of trospium chloride.

Authors:  Oxana Doroshyenko; Alexander Jetter; Karl P Odenthal; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  [Medical therapy of urinary incontinence].

Authors:  M Oelke; J J de la Rosette; M C Michel; U Jonas
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

Review 5.  Trospium chloride in the management of overactive bladder.

Authors:  Eric S Rovner
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  [Overactive bladder--treatment with antimuscarinic agents].

Authors:  K Höfner
Journal:  Urologe A       Date:  2003-05-20       Impact factor: 0.639

Review 7.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria.

Authors:  Julian F Guest; Dele Abegunde; Francis J Ruiz
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 9.  Pharmacotherapy of urinary incontinence.

Authors:  Anastasios Athanasopoulos; Petros Perimenis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-11-12

Review 10.  Female neurogenic vesicourethral dysfunction: evaluation and management.

Authors:  Rebecca J McCrery; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2005-09       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.